Innovative Therapies, Precision Medicine & Diagnostics
Innovative therapies, such as cell and gene therapies, and precision medicine approaches rely on complex technologies. They may also involve different regulated product types, such as biologics, medical devices and in vitro diagnostics. These fields are evolving rapidly. Growing scientific insight and clinical evidence have supported the development of highly effective therapies for rare diseases, with treatments also in development for more prevalent and chronic conditions.
Developing these therapies requires the integration of complex technologies, whether in manufacturing processes or in the molecular evaluation of disease biology. Regulators, policymakers and payers are adapting their approaches in response. This track will examine changes around the world and ask: how does Europe compare?
Who Is This Track Designed For?
This track is designed for developers of innovative therapies, precision medicines and diagnostics; biologics and in vitro diagnostic regulators; policymakers; industry leaders; academics; patients; HTA body representatives; and payers.